Lomardexamfetamine | 1032291-80-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Lomardexamfetamine
• 英文别名: (2S)-2-amino-6-(diaminomethylideneamino)-N-[(2S)-1-phenylpropan-2-yl]hexanamide
• CAS: 1032291-80-7
• 化学式: C₁₆H₂₇N₅O
• 分子量: 305.42
• InChiKey: DRLPEFJOKVYESM-JSGCOSHPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  3

文献信息

• [EN] METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LA PRÉPARATION DE CONJUGUÉS D'AMPHÉTAMINE ET DE SELS DE CEUX-CI
  申请人：CAMBREX CHARLES CITY INC

  公开号：WO2010148305A1

  公开（公告）日：2010-12-23

  The invention provides methods and compositions for preparing amphetamine conjugates, such as lisdexamfetamine, homoarginine-D-amphetamine, and salts thereof. In one embodiment, the invention provides methods of preparing an amphetamine conjugate from a chloramphetamine intermediate.

  这项发明提供了制备苯丙胺共轭物的方法和组合物，例如利斯达氯安非他明、同型精氨酸-D-苯丙胺及其盐。在一个实施例中，该发明提供了从氯苯丙胺中间体制备苯丙胺共轭物的方法。
• [EN] AMPHETAMINE PRODRUG AND CRYSTALLINE FROMS THEREOF<br/>[FR] PROMÉDICAMENT D'AMPHÉTAMINE ET FORMES CRISTALLINES ASSOCIÉES
  申请人：SHIRE PHARMACEUTICALS INC

  公开号：WO2019199731A1

  公开（公告）日：2019-10-17

  The present invention relates to crystalline forms of amphetamine-homoarginine conjugate 1- homoarginine-d-amphetamine, which is an amphetamine prodrug useful in the treatment of various diseases and conditions, and symptoms associated therewith.

  本发明涉及苯丙胺-同型精氨酸共轭物1-同型精氨酸-d-苯丙胺的晶型形式，该化合物是一种苯丙胺前药，可用于治疗各种疾病和症状，并与之相关的症状。
• [EN] HOMOARGININE PRODRUGS AND/OR CONJUGATES OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME<br/>[FR] PROMÉDICAMENTS DE L'HOMOARGININE ET/OU CONJUGUÉS D'AMPHÉTAMINES ET D'AUTRES STIMULANTS ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：KEMPHARM INC

  公开号：WO2013019187A1

  公开（公告）日：2013-02-07

  Disclosed are homoarginine amphetamine prodrug and/or conjugate compositions, salts thereof, or a combination thereof that can reduce or prevent amphetamine side effects in a human subject, and methods to reduce or prevent amphetamine side effects in a human subject.

  本文披露了一种同型精氨酸苯丙胺前药和/或结合物组合物，其盐或二者的组合物可以减少或预防人体主体中苯丙胺的副作用，并提供了减少或预防人体主体中苯丙胺副作用的方法。
• HOMOARGININE PRODRUGS AND/OR CONJUGATES OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME
  申请人：Mickle Travis

  公开号：US20140171510A1

  公开（公告）日：2014-06-19

  Disclosed are homoarginine amphetamine prodrug and/or conjugate compositions, salts thereof, or a combination thereof that can reduce or prevent amphetamine side effects in a human subject, and methods to reduce or prevent amphetamine side effects in a human subject.

  本文公开了一种同型精氨酸苯丙胺前药和/或结合物组合物，其盐或二者的组合，可以减少或预防人体主体中苯丙胺的副作用，并且提供了减少或预防人体主体中苯丙胺副作用的方法。
• METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF
  申请人：Jass Paul Alan

  公开号：US20120190880A1

  公开（公告）日：2012-07-26

  The invention provides methods and compositions for preparing amphetamine conjugates, such as lisdexamfetamine, homoarginine-D-amphetamine, and salts thereof. In one embodiment, the invention provides methods of preparing an amphetamine conjugate from a chloramphetamine intermediate.